ADAM17 and breast cancer: Studies have shown that ADAM17 inhibitors can promote the proliferation and differentiation of natural killer cells, improve the killing effect of natural killer cells by activating the immune system, and increase the antibody-dependent cytotoxicity of natural killer cells to BC cells, which is expected to be developed as a BC treatment (2017).